13/09/2017 22:27:41

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

Related content
20 Sep - 
Alastair McEwan Steps Down as Chief Operating Officer o..
12 Sep - 
Veloxis Increases Share Capital in Connection with Exer..
16 Aug - 
Veloxis Pharmaceuticals Announces Financial Results for..
Related debate
08:27 - 
Tak. Droppede denne, da jeg følte mig mere "sikker" på ..
22 Sep - 
det er også lettere at spå om noget går af røven til en..
22 Sep - 
Ja sikkert. Jeg glemte også at fortælle at det måske i ..

Company Release no. 19/2017

   

To: NASDAQ Copenhagen A/S                                     Copenhagen, Denmark, 13 September 2017

   

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

 

Veloxis Pharmaceuticals A/S is pleased to announce that Veloxis Pharmaceuticals, Inc. has hired Ulf Meier-Kriesche, MD, to serve as its Chief Scientific Officer.  In this role, Dr. Meier-Kriesche will oversee the Company’s regulatory and medical affairs departments.

Dr. Meier-Kriesche is a board certified Nephrologist with over 20 years of practical clinical experience in transplantation.  He is the author of over 170 scientific publications that have appeared in numerous peer-reviewed journals.  Additionally, Dr. Meier-Kriesche served on the faculty of the University of Florida Medical School from 2001 until 2011.   

Prior to joining Veloxis, Dr. Meier-Kriesche was the Clinical Trials Lead Immunology at Bristol-Myers Squibb.  Dr. Meier-Kriesche has also worked for Astellas Pharma.    

Craig Collard, CEO of Veloxis Pharmaceuticals A/S said “Veloxis is committed to serving the needs of the transplant community and the appointment of Ulf Meier-Kriesche further solidifies that commitment.  Ulf’s background and experience as a transplant nephrologist will help Veloxis be more responsive to the concerns of clinicians and ultimately better support the transplant community.”

Ulf Meier-Kriesche commented “I am thrilled to join Veloxis because of the wonderful opportunity we have together to bring new therapeutic options to transplant patients.”

 

For more information, please contact:

Craig A. Collard            

President & CEO                      

Phone: +1 919 591 3090                     

Email: cac@veloxis.com                      

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  

For further information, please visit www.veloxis.com.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
21 Sep
VELO
Aktien er vel faldet noget der ligner 45% siden manden tiltrådte i februar 2016. Den burde stige på,..
7
20 Sep
VELO
Tror panikken er lidt selvforstærkende efter vi kom under 1 kr., fordi der har været snakket så mege..
4
18 Sep
VELO
Må indrømme at jeg også havde set/håbet kurs 1 kunne holde. På lidt længere sigt mener jeg Velo skal..
4
22 Sep
VELO
  Hvis du skal satse på denne aktie, så tænker jeg du skal vente til den kommer ned i 34 øre ;-)
3
18 Sep
VELO
Griner du også hvis din nabo dør af kræft? Du kunne godt virke som typen. Der må bestemt være sket ..
3
20 Sep
VELO
Velo-trenden opdateret     https://invst.ly/57mr8
2
20 Sep
VELO
Pedersen ... det kan sagtens være en ny Exiqon. Handelsmønstret ligner hinanden. Uanset hvor gode ny..
2
20 Sep
VELO
Hej Billemand   Ham din gode ven,  jeg har lige glemt hans navn, ham der siden i hvert fald Nov. sid..
2
19 Sep
VELO
Der er ingen klare støtter  før 0,85 og indikatorerne er nedtrend efter brud af 1,05 og lige nu er d..
2
19 Sep
VELO
Jeg tror ikke lasse477 er mere end 30-35 år. Vi er begge på overførselsindkomst derfor har vi så god..
2

Alliance Trust PLC : Net Asset Value(s)

25/09/2017 13:10:52
ALLIANCE TRUST PLC                                    At the close of business on Friday 22 September 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 748.1p -       including income, 756.0p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding in..

Form 8.5 (EPT/RI) - Booker Group plc

25/09/2017 08:07:28
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Alliance Trust PLC : Transaction in Own Shares

25/09/2017 07:39:49
25 September 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 22 September 2017 the Company purchased for cancellation 54,330 ordinary shares of 2.5p each at a price of 704.6964p per share.  Therefore, the total number of voting rights in the Company is now 349,635,321.    The above figure (349,635,321) may be used by sh..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Gigya, the Market Leader in Customer Identity and Access Management, to be Acquired by SAP
2
iLOOKABOUT Launches New Mobile Appraiser Product at IAAO Conference
3
Aerojet Rocketdyne Supports ULA Launch of Classified Satellite for the U.S. Government
4
OCEANTEAM ASA - Dutch Jos van Dijk appointed Group Chief Financial Officer (CFO)
5
Thinfilm Launches NFC Scanner App for iPhones as Apple Extends NFC Functionality Beyond Payments with Release of iOS 11

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 September 2017 14:27:06
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170921.1 - EUROWEB3 - 2017-09-25 15:27:06 - 2017-09-25 14:27:06 - 1000 - Website: OKAY